Jan 23, 2025, 16:29
FDA approval: Zenocutuzumab for NRG1+ NSCLC – IASLC
The International Association for the Study of Lung Cancer (IASLC) shared a post on X:
“ICYMI, the FDA recently approved zenocutuzumab for NSCLC with an NRG1 fusion.
Catch this all-new episode of Lung Cancer Considered as Stephen V Liu and Alison Schram discuss this breakthrough and what this approval means for treating NSCLC patients with an NRG1 fusion
More posts featuring IASLC.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 23, 2025, 16:29
Jan 23, 2025, 16:29
Jan 23, 2025, 16:03
Jan 23, 2025, 16:00
Jan 23, 2025, 15:56
Jan 23, 2025, 15:43